EIP

CervoMed is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, primarily through the advancement of its lead candidate, neflamapimod. Formed through the 2023 merger of EIP Pharma and Diffusion Pharmaceuticals, the company targets synaptic dysfunction, a key driver of cognitive and motor decline in brain disorders. Neflamapimod is an oral, brain-penetrant small molecule that inhibits p38 alpha MAPK, an enzyme associated with inflammation-induced synaptic toxicity. The company's primary focus is the Phase 2b RewinD-LB study for dementia with Lewy bodies (DLB), where neflamapimod has shown potential as a disease-modifying therapy. CervoMed is also exploring applications in stroke recovery and early-onset Alzheimer's disease.